MedGene Therapeutics
Silver Spring
About MedGene Therapeutics
MedGene Therapeutics is focused on developing ACT treatments (PMBC derived tumor-reactive T cells-Natural Unmodified CD8+ lymphocytes) for two cancers’MSTS (metastatic soft tissue sarcoma) and MFTC (metastatic follicular thyroid cancer)’using NIH patented technology with Worldwide Exclusive License Agreement of commercialization.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $1.2M
- Funding stage: Seed
- Last round: Grant (Aug 2023)
- Website: medgenetx.com
- Phone: (301) 500-6746
Industries & Categories
Biotechnology, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/medgene-therapeutics-131076 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.